People are trying to figure out ways to impact drug pricing short of outright regulation. One idea was to sensitize consumers to prices by mandating inclusion in any advertising. A research letter in the Journal of the American Medical Association Internal Medicine explores what effect this might have. (JAMA Article) CMS has proposed that drug companies must disclose pricing in any television advertising. The researchers recruited 580 subjects through an Amazon job board. People were told to assume they had recently been diagnosed with Type 2 diabetes. They were then shown a made-up ad for a made-up diabetes drug. There were 5 versions of the ad; one made no mention of price and the other four did give a price, ranging from $50 per month to $15,500 per month. Two of the ads were modified with statements saying that consumers could get the drug for as little as zero per month, which is how drug companies would promote copay assistance programs. After looking at the ad, consumers were asked about the likelihood they would ask their physician or insure about getting it, would do online research about it or would use it. They were also asked about what they expected the out-of-pocket cost to be and how effective they thought the medication would be. When the drug was described as low-cost, behavior in terms of asking an insurer or a physician about it, researching it or using it, was unchanged from seeing the ad with no price information. But for high-cost drugs, seeing the cost did cause a fairly significant drop in any of these behaviors. Adding the modifier about the actual cost to the consumer, however, resulted in consumers being more willing to consider the high-price drug. There was no change in expectations of effectiveness between low-cost and high-cost drugs. The research, while methodologically less than optimal (you couldn’t use real patients with a disease and real drugs?), suggests that being aware of price, both in a total sense and the portion likely to be borne by the consumer, can have an impact on behavior.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Two health care firms owned by private equity firms are merging in a transaction supposedly valued at $3 billion. HealthComp administers self-funded plans for employers and other groups and Virgin...
September 27, 2023
NextGen, an electronic medical records firm, is being put out of its public company misery, as a PE firm will pay $1.6 billion for the one-time high-flier.
September 7, 2023
A number of companies which attracted large financing rounds during the epidemic have imploded when reality set in. The latest is Cano Health, which is a little surprising since it...
August 15, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace